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The efficacy of bevacizumab has not been determined for treatment-refractory meningiomas. We treated meningiomas
with low-dose bevacizumab and compared the radiological responses of non-irradiated meningiomas with previously
irradiated meningiomas. In addition, we assessed intraparenchymal radiation necrosis following bevacizumab treatment.
Six patients with meningiomas (three anaplastic, one atypical, and two grade I) who were previously treated with
multiple sessions of radiotherapy and subsequently developed perilesional edema were treated with bevacizumab. Of
six patients, two patients with anaplastic meningiomas developed three tumors following radiotherapy, which were
defined as non-irradiated tumors. There were 12 pre-existing extra-axial tumors that were previously irradiated. Some
of these tumors demonstrated adjacent intraparenchymal contrast enhancement. These tumors were defined as
post-irradiated tumors. Four patients had intraparenchymal radiation necrosis. Low-dose bevacizumab was administered
biweekly over 3–6 cycles to all patients.
Four tumors decreased in contrast-enhanced volume, nine tumors were unchanged, and two tumors progressed. Of the
three non-irradiated tumors, two tumors increased in volume (126 % and 198 %) and one tumor was stable (−5 %). The
median reduction rates determined by contrast volume were −31 % and −71 % in post-irradiated tumors and radiation
necrosis, respectively. Non-irradiated tumors had a significantly poorer response to bevacizumab than post-irradiated
tumors and radiation necrosis (p = 0.0013 and p = 0.0005, respectively, Tukey-Kramer test).
Low-dose bevacizumab did not demonstrate efficacy in the treatment of non-irradiated meningiomas. Responses to
low-dose bevacizumab could be related to its effect on post-irradiation changes, rather than its effect on biologically
active tumor tissue in post-irradiated meningiomas. Radiological responses to low-dose bevacizumab may distinguish
biologically active tumors from post-irradiation changes in progressive meningiomas following radiotherapy.
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High-grade meningiomas and benign skull base men-
ingiomas are difficult to treat with surgical resection
alone; therefore, these meningiomas are usually treated
with surgical resection in combination with radiother-
apy. In high-grade meningiomas, the efficacy of standard
radiotherapy is limited and high-dose radiotherapy, in-
cluding stereotactic radiosurgery, particle radiotherapy,* Correspondence: neu054@poh.osaka-med.ac.jp
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nately, these high-dose radiotherapies and multiple ses-
sions of radiotherapy increase the frequency of radiation
injury, including radiation necrosis. Chemotherapeutic
agents are generally ineffective on meningiomas; how-
ever, two recent reports have demonstrated that anaplas-
tic meningioma partially shrank after bevacizumab
treatment [4, 5]. However, both tumors in this report
had been previously irradiated, and intratumoral or peri-
tumoral post-irradiation changes that caused angiogen-
esis may be mistaken for tumor tissue and incorrectlyticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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including ours, have demonstrated that bevacizumab,
which is an anti-vascular endothelial growth factor
(VEGF) antibody, is effective in treating radiation necro-
sis of the brain [6–10]. VEGF is expressed in regions ad-
jacent to necrotic cores of radiation necrosis, promoting
angiogenesis and perilesional edema [11, 12]. It has also
been reported that VEGF is expressed in meningiomas
[13]. Distinguishing viable and active tumor tissues from
post-irradiation changes by magnetic resonance (MR)
imaging is challenging. Therefore, the true efficacy of
bevacizumab treatment for either viable high-grade or
treatment-refractory meningiomas remains unknown.
In the present study, we administered low-dose bevaci-
zumab to patients with meningiomas previously treated
with radiotherapy for the treatment of recently developed
perilesional edema. Our aim of using bevacizumab treat-
ment was initially to reduce perilesional edema and mass
effect. At the commencement of bevacizumab treatment,
some patients with anaplastic meninigomas developed
new tumors, which had not been irradiated. We retro-
spectively evaluated the response of non-irradiated ana-
plastic meningiomas to bevacizumab. We also compared
the response to bevacizumab between non-irradiated tu-
mors and previously irradiated tumors, which may include
intratumoral or peritumoral post-irradiation changes.
Methods
Six patients with meningiomas (three anaplastic, one
atypical, and two grade I) were treated with bevacizumab
between August 2012 and January 2014. All patients had
undergone surgical resection and multiple sessions of
radiotherapy, and recently developed massive perile-
sional edema. There were three non-irradiated tumors
that had developed after radiotherapy in two patients
with anaplastic meningiomas. These tumors were de-
fined as “non-irradiated tumors.” All patients had tu-
mors that had been previously treated with radiotherapy.
Some pre-existing extra-axial tumors were heteroge-
neously enhanced by contrast media and accompanied
by adjacent parenchymal contrast-enhancement. These
lesions likely represent both viable tumor tissue and
post-irradiation changes and were defined as “post-irra-
diated tumors.” There were 12 pre-existing extra-axial
post-irradiated tumors in six patients. Four patients had
intraparenchymal contrast-enhanced lesions that were
not contiguous with extra-axial tumors. These lesions
were defined as “radiation necrosis.”
The initial aim of bevacizumab treatment was to re-
duce perilesional edema. Bevacizumab was intravenously
administered at a dose of 5 mg/kg bi-weekly over 3–6
cycles. The time between the last radiotherapy session
and the commencement of bevacizumab treatment
ranged from 2.5 to 17 months (median 6 months). Theresponse to bevacizumab was evaluated using volumetric
analysis. The volume of a measurable extra-axial enhanced
tumor or a measurable intraparenchymal enhanced radi-
ation necrosis was calculated from the sum of the en-
hanced area on each slice of gadolinium-enhanced T1-
weighted MRI multiplied by the slice thickness. The
volume of perilesional edema identified as hyperintense
lesions on fluid attenuated inversion recovery (FLAIR)
imaging was calculated in the same manner. The reduc-
tion rate due to bevacizumab was calculated by dividing
the pre-treatment volume subtracted from the post-
treatment volume by the pretreatment volume. “Response”
was defined as a 50 % reduction (−50 %). “Progression”
was defined as a 25 % increase (25 %). Lesions that were
categorized as neither “response” nor “progression” (−49–
24 %) were defined as “stable.” The study protocol was ap-
proved by the Osaka Medical College Ethics Committee.
Results
Study patient demographics and tumor characteristics
are shown in Table 1. Bevacizumab was administered for
6 cycles in two patients, 4 cycles in one patient, and 3
cycles in three patients. There were no apparent adverse
events during bevacizumab treatment.
In all patients, perilesional edema improved following
bevacizumab treatment. Perilesional edema reduced by
between −90 % and −29 % compared to pretreatment
edema (median −46 %). The median change in contrast
enhanced tumor volume of 15 meningiomas in response
to bevacizumab was −10 % compared to pretreatment
tumor volumes (range −89–198 %). Four tumors demon-
strated a response according to tumor volume, nine tu-
mors were stable, and two tumors progressed. Of three
non-irradiated tumors, two tumors in Case 1 progressed
(126 % and 198 %, respectively) (Fig. 1a, b, d, e) and one
tumor in Case 2 was stable (−5 %) (Fig. 1c, f ). On the
other hand, all post-irradiated tumors were controlled by
bevacizumab (Fig. 1c, f, Fig. 2a, b, d, e). The median re-
duction rate of post-irradiated tumors was −31 % (−89–19
%). With regard to radiation necrosis, contrast-enhanced
intraparenchymal lesions were decreased in all patients
(Fig. 1c, f, Fig. 2a, c, d, f ). The median reduction rate of
radiation necrosis was −71 % (−100–−51 %) (Table 2).
There was a significant difference of the reduction rate
between non-irradiated tumors, post-irradiated tumors,
and radiation necrosis (p = 0.0005, ANOVA) (Fig. 3). Non-
irradiated tumors responded significantly poorer than
post-irradiated tumors and radiation necrosis (p = 0.0013
and p = 0.0005, respectively, Tukey-Kramer test). However,
there was not a significant difference between post-
irradiated tumors and radiation necrosis (p = 0.3155,
Tukey-Kramer test). Clinically, the symptoms of three pa-
tients improved after bevacizumab, whereas those of the
other three patients did not change.





Lesion Location Radiotherapy Bev from
RT (month)
Reduction Rate Outcome
FLAIR ( %) Gd ( %) Radiological Clinical
Case 1 70 F anaplastic 4 Tumor 1
(non-irradiated)
R frontal (cranial) N/A −71 198 Progression Improved L hemiparesis
Tumor 2
(non-irradiated)
R frontal (caudal) N/A 126 Progression
Tumor 3 R frontal SRT 32Gy 8 −89 Response
Tumor 4 R frontotemporal SRS 23Gy/SRS 20Gy/
SRS 22Gy/ SRT 33Gy
3 7 Stable
Case 2 52 M anaplastic 3 Tumor 5 occipital SRS 14Gy/ SRS 14Gy/
SRT 25.5Gy/BNCT
13 −47 −10 Stable Unchanged dizziness and
visual disturbance
Tumor 6 L temporal SRT 27Gy 20 −79 Response
Tumor 7
(non-irradiated)
R temporal N/A −5 Stable
Tumor 8 L tentorial edge SRS 20Gy 2.5 −55 Response
Case 3 76 F atypical 6 Tumor 9 parasagittal SRT 24Gy/ BNCT 8 −29 0 Stable Unchanged L hemiparesis
Case 4 52 M grade I 3 Tumor 10 petroclival GKR 14Gy/RT 30Gy/
GKR 14Gy
5.5 −33 −14 Stable Improved R hemiparesis and
L ataxia
Case 5 69 F grade I 3 Tumor 11 parasagittal SRS/ SRS 13 −90 −47 Stable Improved gait disturbance
Case 6 46 F anaplastic 6 Tumor 12 frontal base EBRT 60Gy/ BNCT/BNCT 4 −45 −48 Stable Unchanged cognitive dysfunction
Tumor 13 orbit BNCT/BNCT 4 −65 Respose
Tumor 14 infratemporal BNCT/BNCT 4 12 Stable











Fig. 1 MR images before and after bevacizumab in Case 1 (before, a, b; after, d, e) and Case 2 (before, c; after, f). There were three non-irradiated
tumors (a, white arrow: tumor 1; b, white arrow: tumor 2; c, white arrow: tumor 7). After bevacizumab, both Tumors 1 and 2 showed progression
(d, e: arrows). Tumor 7 did not changed after bevacizumab treatment (f: arrow). On the other hand, a post-irradiated tumor decreased after
bevacizumab. Tumor 6 decreased to −79 % (c, f: arrowheads). Intraparenchymal radiation necrosis was disappeared (c, f: black arrow)
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High-grade meningiomas and deep-seated benign men-
ingiomas are difficult to manage. Any chemotherapeutic
agent had not been shown to be effective on meningi-
omas [14–16]. Recently, there were some reports that
bevacizumab was used for meningiomas (Table 3) [4, 5,
17–20]. Lou et al. reported 14 cases of meningiomas
treated with bevacizumab [5]. Ten of 14 patients had
undergone prior radiotherapy, and bevacizumab was
used as monotherapy in four patients and in combin-
ation with other chemotherapeutic agents in 10 patients.
Treatment efficacy was evaluated using the Response
Assessment in Neuro-Oncology [21]. There was no
complete response (CR), but a partial response (PR) in
one patient, stable disease in 11 patients, and progressive
disease in two patients were observed. The authors
noted that there was a general trend toward increased
progression-free survival in patients who had receivedstereotactic radiotherapy. In another case series, Nayak
L et al. reported that grade II and III meningiomas were
treated with bevacizumab [18]. Neither CR nor PR was
obtained, and the best response was stable disease.
There are two more case reports demonstrating that
bevacizumab was used for malignant meningiomas [4,
20]. Both tumors had already irradiated before bevacizu-
mab. The tumor partially responded to bevacizumab in
one case and multiple tumors were stable or slowly
growing after bevacizumab in the other case. There was
no report that a non-irradiated anaplastic meningioma
responded to bevacizumab. Nunes et al. treated neuro-
fibromatosis type 2-related meningiomas with bevacizu-
mab [19]. Fourteen patients had progressive vestibular
schwannomas and coexisting meningiomas and one pa-
tient had progressive meningioma. They retrospectively
analyzed the response to bevacizumab and found that
tumor volume was reduced by 20 % or more in 29 % of
Fig. 2 MR images before and after bevacizumab in Case 3 (before, a; after, d) and Case 6 (before, b, c; after, e, f). Intraparenchymal radiation
necrosis decreased to −65 % and −51 % after bevacizumab in Cases 3 and 6, respectively (black arrows). Regarding post-irradiated tumors, Tumor
9 (Case 3) (a, d, arrowhead) did not change (0 %) and Tumor 13 (Case 6) (b, e, arrowhead) showed 65 % decrease after bevacizumab
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the response of a coexisting convexity meningioma to bev-
acizumab in a patient with neurofibromatosis type 2 (the
target of bevacizumab treatment was a vestibular schwan-
noma) [17]. The tumor size was reduced by 22 % after
bevacizumab. VEGF expression tended to increase with
tumor grade; however, the difference did not reach statis-
tical significance [22, 23]. Conversely, the degree of VEGF
expression has been reported to have a positive correlation
with the extent of peritumoral edema [22, 24].
All of anaplastic meningiomas treated with bevacizu-






Case 2 52 M anaplastic 3 Necrosis 1 occip
Case 3 76 F atypical 6 Necrosis 2 para
Case 5 69 F grade I 3 Necrosis 3 para
Case 6 46 F anaplastic 6 Necrosis 4 frontradiotherapy. Our study had three non-irradiated ana-
plastic meningiomas and these tumors were not
responded. Post-irradiated tumors responded to bevaci-
zumab significantly better than non-irradiated tumors.
Likewise, intraparenchymal radiation necrosis also sig-
nificantly responded better than non-irradiated tumors.
Therefore, we presume that enhancement by contrast,
which is attenuated or disappears after bevacizumab
treatment, may be an intratumoral or peritumoral post-
irradiation change. Our previous studies have shown
that low-dose bevacizumab is also effective for radiation






ital SRS 14Gy/ SRS 14Gy/
SRT 25.5Gy/BNCT
13 −100 Response
sagittal SRT 24Gy/ BNCT 8 −65 Response
sagittal SRS/ SRS 13 −76 Response
al EBRT 60Gy/ BNCT/BNCT 4 −51 Response
Fig. 3 Graph demonstrating the reduction rate of non-irradiated meningiomas, post-irradiated meningiomas, and intraparenchymal radiation
necrosis. Non-irradiated tumors responded significantly poorer than post-irradiated tumors and radiation necrosis (p = 0.0013, p = 0.0005, respectively,
Tukey-Kramer test)
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including radiation necrosis. In the present study, how-
ever, low-dose bevacizumab was not effective for treating
non-irradiated anaplastic meningiomas. Post-irradiated
tumors responded in various degrees to bevacizumab.
The reason was that viable tumor tissue and post-
irradiation changes could be coexistent in tumors previ-
ously treated with radiotherapy and a section of post-
irradiation change may be influenced by reduction rate to
bevacizumab. It is difficult to distinguish between these
two pathologies in post-irradiated tumors using conven-
tional MR sequences. However, the diagnostic ability of
MRI has recently progressed. On diffusion-weighted MRI,
the apparent diffusion coefficient reflecting cellular dens-
ity has been shown to be useful in differentiating post-
irradiation effects from tumor recurrence or progression
in high-grade gliomas [25]. Dynamic contrast-enhanced
MR perfusion study has also shown its utility for distin-
guishing these two pathologies in gliomas [26]. In a recent
study, multiparametric clustering MR imaging data dem-
onstrated greater diagnostic accuracy in differentiating
tumor progression from post-treatment change than did a
single parameter method such as ADC or each perfusion
parameter [27]. In diagnostic nuclear medicine, recurrent
and progressive meningiomas show a high uptake of
18F-FDG, 11C-methionine, and 18F-boronophenylalanine
on PET [28–30], and PET may differentiate between vi-
able tumor tissues and post-irradiation changes in malig-
nant meningiomas after radiation therapy. However, PET
is not as widely available as MRI.In our series, all patients showed progression of perile-
sional edema before bevacizumab treatment. In this con-
dition, it is sometimes difficult to judge whether the main
cause of perilesional edema is either tumor progression or
post-irradiation changes. It could be to be desired that
low-dose bevacizumab is firstly used to improve patients
status when the lesion is not conclusively diagnosed as ei-
ther a tumor progression or post-irradiation changes. In
our study, half of the patient’s neurological symptoms
were ameliorated, reducing perilesional edema. Low-dose
bevacizumab is expected to provide clinical benefits in pa-
tients with symptomatic perilesional edema irrespective of
the pathology of the enhanced lesion. Low-dose bevacizu-
mab could reduce contrast enhancement if a tumor in-
cludes post-irradiation changes. Residual enhanced lesion
after bevacizumab may be mostly a viable tumor tissue. If
bevacizumab is not effective and a large enhanced lesion
still exists, then additional radiotherapy or surgical resec-
tion could be a treatment option to control disease. Pre-
ceding bevacizumab would avoid unnecessary additional
radiotherapy for post-irradiated tumor.
Conclusions
Three non-irradiated anaplastic meningiomas did not re-
spond to low-dose bevacizumab in our study. Some
post-irradiated meningiomas responded to bevacizumab.
Post-irradiated meningiomas had heterogeneous path-
ology; residual or recurrent active tumors coexisted with
post-irradiation changes. Intratumoral and peritumoral
post-irradiation changes, but not viable tumor tissue,
Table 3 Review of literatures reporting bevacizumab treatment for meningiomas




et al. 2010 [4]
1 Anaplstic 60Gy RT 10 mg/kg every
2 weeks
6 months N/A 1 PR N/A hypertension
Goutagny S,
et al. 2011 [17]
7 tumors in
NF2 pts
none 5 mg/kg Every
2 weeks




Lou E, et al.
2012 [5]
5 GI RT: 12/14 10 mg/kg very
2 weeks
0.5–29.5 months RANO 0 CR mPFS: 17.9 months Tumoral hemorrhage
5 GII CT: 11/14 1 PR PFS-6: 85.7 % G4 intestinal perforation
3 GIII 11 SD G5 pneumonia/sepsis
1 unk 2 PD
Nayak L, et al.
2012 [18]
6 GII RT: 15/15 10 mg/kg every
2 weeks
9 doses (1–19 doses) RANO 0 CR mPFS: 26 weeks G1 Intratumoral hemorrhage
9 GIII CT: 7/15 0 PR mOS: 15 months G2 fatigue
15 SD
Nunes FP, et al.
2013 [19]
48 tumors







Per-tumor 4 G3 events
Progression: 20 %
increase
Patients PFS-6: 85 % 2 G4 events (wound
healing problems)
7 % response Per-patient
PFS-6: 93 %
Boström JP,
et al. 2014 [20]
1 GIII 60Gy RT 5 mg/kg
every 2 weeks














Furuse et al. Radiation Oncology  (2015) 10:156 Page 8 of 8may respond to low-dose bevacizumab in previously ir-
radiated meningiomas. MR imaging after low-dose beva-
cizumab treatment could be used to differentiate active
tumors from post-irradiation changes on the basis of the
response of contrast enhanced lesions in post-irradiated
meningiomas.
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